Tidal volume

PMD Solutions Supports RSRT's Biosensor VIBRANT Study for Rett Syndrome with Donation of FDA-cleared RespiraSense Devices and Analytics

Retrieved on: 
Thursday, March 28, 2024
Emerald, Emory University, Doctor of Philosophy, ECG, Partnership, Respiratory rate, Heart rate, Patient, Research, Neurodevelopmental disorder, RSRT, Dysautonomia, Sleep, Artificial intelligence, Rett syndrome, Tidal volume, Radio, PMD, FDA, Movement, Pharmaceutical industry

TRUMBULL, Conn., March 28, 2024 /PRNewswire-PRWeb/ -- The Rett Syndrome Research Trust (RSRT) is proud to announce its partnership with PMD Solutions, a leading provider of innovative healthcare technologies, in their upcoming biosensor validation study called VIBRANT. PMD Solutions will generously donate their state-of-the-art RespiraSense devices and advanced analytics to support RSRT's efforts in assessing autonomic dysfunction in individuals with Rett syndrome, utilizing cutting-edge digital technologies.

Key Points: 
  • PMD Solutions will generously donate their state-of-the-art RespiraSense devices and advanced analytics to support RSRT's efforts in assessing autonomic dysfunction in individuals with Rett syndrome, utilizing cutting-edge digital technologies.
  • PMD Solutions will generously donate their state-of-the-art RespiraSense devices and advanced analytics to support RSRT's efforts in assessing autonomic dysfunction in individuals with Rett syndrome, utilizing cutting-edge digital technologies.
  • The integration of RespiraSense devices with PMD Solutions' cutting-edge analytics offers a comprehensive solution for tracking and analyzing breathing parameters in Rett syndrome patients.
  • By donating RespiraSense devices and analytics for RSRT's biosensor validation study, PMD Solutions will contribute significantly to the advancement of RSRT's mission to cure Rett syndrome.

Humanetics Corporation Publishes Positive Clinical Trial Results of BIO 300 in Patients with Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, September 19, 2023
Contracts, Law Enforcement, Emergency Services, Pharmaceutical, Oncology, General Health, Defense, Seniors, Public Policy, Government, Men, Clinical Trials, Family, Science, Consumer, Health, Research, Tidal volume, BIO, Radiation, COVID-19, Survival, Clinical trial, Cancer, Quality of life, Pharmacokinetics, Toxicity, Lung cancer, Radiation therapy, Pulmonary fibrosis, Humanetics, Patient, Canadian International Council, Risk, Neoplasm, Pulmonary toxicity, Chemoradiotherapy, Human, Safety, Medical imaging, Pharmaceutical industry, NSCLC

A recently published paper in the International Journal of Radiation Oncology – Biology – Physics (Red Journal) details encouraging results from a multicenter clinical study conducted with Humanetics Corporation’s (Humanetics) novel radioprotective drug, BIO 300, in patients with non-small cell lung cancer (NSCLC).

Key Points: 
  • A recently published paper in the International Journal of Radiation Oncology – Biology – Physics (Red Journal) details encouraging results from a multicenter clinical study conducted with Humanetics Corporation’s (Humanetics) novel radioprotective drug, BIO 300, in patients with non-small cell lung cancer (NSCLC).
  • Twenty-one patients were enrolled in the phase 1b/2a study evaluating the safety and clinical utility of BIO 300 as a radioprotector of normal tissues in patients with NSCLC ( NCT02567799 ).
  • In addition, patients receiving BIO 300 had a lower rate of hematological, pulmonary, and gastrointestinal toxicities compared to previous clinical studies with the same chemoradiotherapy regimen in the absence of BIO 300.
  • BIO 300 is also under advanced development as a radiation medical countermeasure for the military and first responders, and BIO 300 is in a phase 2b trial evaluating the clinical utility of BIO 300 to protect lung tissues against the long-term effects of COVID-19 ( NCT04482595 ).

World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China.

Retrieved on: 
Thursday, November 24, 2022
Health, Infectious Diseases, COVID-19, Clinical Trials, Research, Science, Pharmaceutical, Safety, Public health, Convidecia, VLP, Pain, International Society, CanSino Biologics, National Medical Products Administration, Research, Ageing, Tidal volume, Multimedia, Noble gas, Atmosphere of Earth, Chronic obstructive pulmonary disease, COVID-19, Partnership, Severe acute respiratory syndrome coronavirus 2, McGrath, Adenoviridae, Vaccine, Nassar Ikram, WHO, News, Enterprise Ireland, Mechanical, Mechanical ventilation, Vaccination, Use, Effect, Growth, DOI, Diagnosis, Inhalation, COPD, Medtech, Ventilation, Patient, Global Initiative, HKEX, McLoughlin, SSE, COVID19, Pharmaceutical industry, Medical device, Lancet, Medicine

This route mimics the natural infection pathway of the respiratory virus COVID-19 and may create additional benefits through generating mucosal immunity.

Key Points: 
  • This route mimics the natural infection pathway of the respiratory virus COVID-19 and may create additional benefits through generating mucosal immunity.
  • 2,3
    Further clinical trials of the inhaled vaccine are progressing in Asia and Latin America to support other country approvals for this innovative technology.
  • John Power, Aerogen CEO & Founder said The world has an urgent need for an effective, low-cost, globally scalable, and globally accessible solution to mass vaccination.
  • We are delighted with the news of approval and public rollout in China and look forward to further approval of inhaled vaccines around the world.

Global $1 Billion Anesthesia Disposables Markets, Analysis, & Forecasts 2016-2021, 2021-2026F, 2031F - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 26, 2022
Surgery, Health, Medtronic, EPA, Physician, Pain, Population, NJCAA National Football Championship, American Association of Nurse Anesthetists, Airway management, Press Uncuffed, AAMC, Respiratory disease, Patient, Thyroid disease, Association, Arthritis, Anesthesia, Pediatrics, UK, ETT, Teleflex, Child, Center, Health Education England, Doctor of Nursing Practice, Ageing, American Association, Oxygen, Growth, Mercury, Prevalence, Tidal volume, Anesthesiology, Cardiovascular disease, Nurse anesthetist, Dentistry, Medicine

The anesthesia disposables market consists of sales of anesthesia disposables and related services.

Key Points: 
  • The anesthesia disposables market consists of sales of anesthesia disposables and related services.
  • The anesthesia disposables are easy to use and portable devices.
  • The increase in the aging population leads to increased surgeries driving the anesthesia disposable market.
  • Global Anesthesia Disposables Forecast Market, 2021-2026F, 2031F, $ Billion

Wave Life Sciences Announces Two Papers in the Journal Nucleic Acids Research Describing How PN Backbone Chemistry Modifications Enhance the Pharmacological Effects of Oligonucleotides

Retrieved on: 
Wednesday, February 2, 2022
CNS, Duchenne muscular dystrophy, Private Securities Litigation Reform Act, Patient, Therapy, Amyotrophic lateral sclerosis, Publication, Dementia, Central nervous system, ALS, PN, Neuron, SEC, Tidal volume, FTD, Degenerative disease, Optimism, Research, HD, Oligonucleotide, PRISM, Nucleic Acids Research, U.S. Securities and Exchange Commission, Annual report, Chemistry, List of life sciences, GLOBE, Doctor of Philosophy, Organic acid, Control, Drug development, Security (finance), Mouse, Nucleic acid, MPH, Weight gain, Fine chemical, Pharmaceutical industry, Wave, DMD, MD

CAMBRIDGE, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced two publications in the journal Nucleic Acids Research supporting the incorporation of PN backbone chemistry modifications (PN chemistry) in stereopure oligonucleotides as a significant advancement for the therapeutic oligonucleotide field. In the multitude of in vitro and in vivo (animal) studies highlighted in the papers, PN chemistry dramatically improved potency, distribution, and durability of effect. The papers explore the use of PN chemistry in stereopure silencing oligonucleotides for central nervous system (CNS) diseases and stereopure splicing oligonucleotides for neuromuscular diseases. Wave currently has three ongoing clinical trials investigating PN chemistry-containing compounds for amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD), Duchenne muscular dystrophy (DMD) and Huntington’s disease (HD).

Key Points: 
  • In the multitude of in vitro and in vivo (animal) studies highlighted in the papers, PN chemistry dramatically improved potency, distribution, and durability of effect.
  • The papers explore the use of PN chemistry in stereopure silencing oligonucleotides for central nervous system (CNS) diseases and stereopure splicing oligonucleotides for neuromuscular diseases.
  • These papers on PN chemistry specifically phosphoryl guanidine linkages demonstrate that we have identified an important new opportunity for optimizing therapeutic stereopure oligonucleotides, said Chandra Vargeese, PhD, Chief Technology Officer at Wave Life Sciences.
  • Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases.

Aerogen® and CanSinoBIO agree on landmark development and commercial supply partnership for world’s first inhaled Covid-19 vaccine delivery

Retrieved on: 
Thursday, December 9, 2021
Technology, Mobile, Wireless, Medical Devices, Infectious Diseases, Clinical Trials, Biotechnology, Other Health, Health, Data Management, CanSino Biologics, ISO 10993, Risk, Research, COPD, NMPA, COVID19, Tidal volume, Adenoviridae, SSE, International Society, McLoughlin, Vaccine, Patient, Mechanical ventilation, Partnership, Atmosphere of Earth, Conditional, McGrath, CRM197, Mechanical, Use, Global Initiative, Ventilation, Multimedia, Effect, COVID-19, Public health, HKEX, Diagnosis, Chronic obstructive pulmonary disease, Noble gas, Pharmaceutical industry, Medical device

Following months of collaborative development work, Aerogen (Galway, Ireland) and CanSinoBIO (SSE: 688185, HKEX: 06185) (Tianjin, China) have announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIOs Recombinant Novel Coronavirus Vaccine Convidecia utilizing Aerogens proprietary vibrating mesh aerosol drug delivery technology.

Key Points: 
  • Following months of collaborative development work, Aerogen (Galway, Ireland) and CanSinoBIO (SSE: 688185, HKEX: 06185) (Tianjin, China) have announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIOs Recombinant Novel Coronavirus Vaccine Convidecia utilizing Aerogens proprietary vibrating mesh aerosol drug delivery technology.
  • Dr. Xuefeng YU, Chairman and Chief Executive Officer of CanSinoBIO commented; Our partnership with Aerogen started in 2013 and for almost a decade, weve been advancing the possibility of aerosol drug delivery.
  • The innovative development on the inhaled delivery of COVID-19 vaccine is the testimony of our collaborative efforts.
  • The Aerogen Solo is a closed-system, single-patient-use aerosol drug delivery technology3 that mitigates the transmission of patient-generated infectious aerosol during ventilation4-9.

Anesthesia Disposables Global Market Report 2021 Featuring Ambu A/S, Medline Industries, Smiths Medical, Teleflex and Vyaire Medical - ResearchAndMarkets.com

Retrieved on: 
Friday, August 6, 2021
Pharmaceutical, Health, Medical Supplies, KSR International Co. v. Teleflex Inc., Arthritis, Respiratory disease, Nurse anesthetist, Prevalence, Press Uncuffed, Population, COVID-19, Pediatrics, Patient, Tidal volume, Airway management, Oxygen, Heat and moisture exchanger, Anesthesiology, Cardiovascular disease, Pain, Respiratory arrest, Ageing, HME, ETT, Child, Thyroid disease, Dentistry

The "Anesthesia Disposables Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anesthesia Disposables Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the anesthesia disposables market are Ambu A/S (Denmark), Medline Industries, Inc. (USA), Smiths Medical, (USA), Teleflex, Inc. (USA) and Vyaire Medical Inc. (USA).
  • The anesthesia disposables market consists of sales of anesthesia disposables and related services.
  • These disposables include onetime use anesthesia circuits, anesthesia masks, sample lines, filters/Heat & Moisture Exchangers (HMEs), breathing bag, endotracheal tubes, and laryngeal masks.

Forwardly’s Ligand Innovation Global Makes Significant Strides Towards FDA Submission

Respiratory therapy, Branches of biology, Health care, Anatomy, Lung

After several trial configurations, Ligands engineering team has designed an airway circuitry that delivers maximal tidal volumes even with maximum lung resistance.

Key Points: 
  • After several trial configurations, Ligands engineering team has designed an airway circuitry that delivers maximal tidal volumes even with maximum lung resistance.
  • We have tested the new airway design on a calibrated test lung, and it is working well.
  • A final build of the prototype is expected for late October and an FDA submission should be completed by December 2021.
  • Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated.

Relief Therapeutics Announces Filing of IND for Phase 2/3 Clinical Trial of Inhaled RLF-100 Targeting Early COVID-19 Lung Injury

Retrieved on: 
Monday, May 11, 2020
Medical specialties, Medicine, Clinical medicine, Intensive care medicine, Respiratory therapy, Emergency medicine, Respiratory physiology, Mechanical ventilation, Acute respiratory distress syndrome, Respiratory distress syndrome, Tidal volume, Horowitz index

RLF-100 is already in clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients on mechanical ventilation.

Key Points: 
  • RLF-100 is already in clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients on mechanical ventilation.
  • Our clinical trial partners have asked us to develop a treatment approach for patients presenting with early lung injury in the hopes of preventing progression to ICU care and mechanical ventilation.
  • Patients with early COVID-19 lung injury commonly describe crackling sounds in their lungs, combined with extreme shortness of breath.
  • Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses.

Women are less likely to receive lung protective tidal volumes when being considered as a lung donor

Retrieved on: 
Thursday, October 4, 2018
Organ transplantation, Organ donation, Tidal volume, Biology

The authors found that potential organ donors frequently did not receive appropriate low tidal volumes (Vt) in the transplant evaluation period.

Key Points: 
  • The authors found that potential organ donors frequently did not receive appropriate low tidal volumes (Vt) in the transplant evaluation period.
  • More than half (65 percent) of all patients received excessive Vt during the 48 hours prior to death.
  • Women were more likely to receive excessively high tidal volumes than men (76 percent of women vs 57 percent of men; P<.001>
  • "Multicenter studies are needed to determine the impact of excessive tidal volumes on organ suitability and outcomes."